Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

India’s Zydus Buys Laboratories Combix Of Spain For Generics Market

This article was originally published in PharmAsia News

Executive Summary

Zydus Cadila of India said it has acquired the assets of Laboratories Combix of Spain, but did not disclose the purchase amount. A Zydus official said the takeover would help the firm establish itself as a global health care provider in addition to making generic drugs. The official said Zydus was counting on a rapidly growing market for generics in Spain, already considered the world's fifth-largest market for pharmaceuticals. Combix already has a portfolio of 17 molecules. (Click here for more

You may also be interested in...



India’s Zydus Cadila Buys Majority Stake In South Africa’s Simayla Pharmaceuticals

NEW DELHI - Indian generic drug firm Zydus Cadila said a wholly-owned unit bought a 70 percent stake in South Africa's Simayla Pharmaceuticals of South Africa at an undisclosed price to expand market share in the cardiovascular, anti-infective, respiratory, gastrointestinal and women's healthcare segments

Ready, Set, Guidance: FDA Releases Final Details Ahead Of ASCA Pilot Launch

A trio of newly finalized guidance documents from the US agency dated 25 September explain how the Accreditation Scheme for Conformity Assessment pilot will work, and what biocompatibility and safety standards will apply.

With Preservative-Free Alaway Eye Drops, Bausch Expands OTC Portfolio Of Planned Spin-Off

Approval of Alaway Preservative Free (ketotifen fumarate, 0.035) comes 15 months after FDA submitted a complete response letter to Bausch and the active ingredient developer, Eton Pharmaceuticals. 

UsernamePublicRestriction

Register

MT142639

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel